Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Natural Product (NP) Details

General Information of the NP (ID: NP9583)
Name
Paroxetine
Synonyms
paroxetine; 61869-08-7; Paxil; Paxil CR; Casbol; Seroxat; Paroxetina; Paroxetinum; Aropax; Paroxetinum [INN-Latin]; Paroxetina [INN-Spanish]; BRL 29060; Paxetil; FG 7051; Pexeva; Frosinor; Motivan; PaxPar; (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; (3s,4r)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; BRL-29060; UNII-41VRH5220H; (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine; [3H]Paroxetine; FG-7051; CHEMBL490; (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S,4R)-; CHEBI:7936; 41VRH5220H; C19H20FNO3; 110429-35-1; DSSTox_CID_3425; (3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; Paroxetine (TN); DSSTox_RID_77022; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S-trans)-; DSSTox_GSID_23425; Paroxetine [USAN:INN:BAN]; CHEMBL1708; Paroxetine Base; piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S,4R)-; Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-,(3S,4R)-; (-)-Paroxetine; PAROXETINE HCL HEMIHYDRATE; CAS-61869-08-7; Paroxetine (USP/INN); 3h-paroxetine; Paroxetine.HCl; Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S-trans)-; NCGC00182968-01; 8PR; NNC-20-7051; Spectrum_001752; SpecPlus_000788; Prestwick3_000851; Spectrum5_001665; (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)methyl)piperidine; SCHEMBL27799; BSPBio_000861; KBioSS_002232; BIDD:GT0673; DivK1c_006884; BPBio1_000949; GTPL4790; DTXSID3023425; BDBM22416; HSDB 7175; KBio1_001828; KBio2_002232; KBio2_004800; KBio2_007368; HMS2090H05; ZINC527386; Tox21_113123; BDBM50331515; (-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine; AKOS015888636; Tox21_113123_1; AC-8185; DB00715; SDCCGSBI-0051908.P003; (-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine; (3S-trans)-3-[(1,3-Benzodioxol-5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine; NCGC00025355-02; NCGC00025355-03; NCGC00025355-04; NCGC00025355-05; NCGC00025355-06; NCGC00025355-07; NCGC00025355-08; NCGC00025355-09; NCGC00025355-12; NCGC00025355-22; SBI-0051908.P002; AB00514724; C07415; D02362; AB00053704-21; AB00053704_22; AB00053704_23; Paroxetine Hydrochloride Anhydrous EP Impurity E; 869P087; paroxetine hydrochloride (anhydrous or hemihydrate); Q408471; BRD-K37991163-003-02-7; BRD-K37991163-050-05-1; cis-Paroxetine; Paroxetine USP Related Compound D;[(3S,4R)-4-(p-Fluorophenyl)-3-piperidyl](1,3-dioxa-5-indanyloxy)methane
    Click to Show/Hide
Species Origin Areca catechu ...     Click to Show/Hide
Areca catechu
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Arecales
Family: Arecaceae
Genus: Areca
Species: Areca catechu
Disease Depression [ICD-11: 6A70-6A71] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C19H20FNO3
PubChem CID
43815
Canonical SMILES
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4
InChI
1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1
InChIKey
AHOUBRCZNHFOSL-YOEHRIQHSA-N
CAS Number
CAS 61869-08-7
ChEBI ID
CHEBI:7936
TTD Drug ID
D06GDY
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Everolimus      Renal cell carcinoma     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model SH-SY5Y CVCL_0019 Neuroblastoma Homo sapiens
                    Experimental
                    Result(s)
Combination treatment with Everolimus and Paroxetine showed synergistic post-ischemic neuroprotective efficacy.
Target and Pathway
Target(s) Serotonin transporter (SERT)  Molecule Info  [3]
KEGG Pathway Serotonergic synapse Click to Show/Hide
NetPath Pathway TCR Signaling Pathway Click to Show/Hide
Panther Pathway 5HT1 type receptor mediated signaling pathway Click to Show/Hide
2 5HT2 type receptor mediated signaling pathway
3 5HT3 type receptor mediated signaling pathway
4 5HT4 type receptor mediated signaling pathway
WikiPathways Monoamine Transport Click to Show/Hide
2 SIDS Susceptibility Pathways
3 NRF2 pathway
4 Synaptic Vesicle Pathway
5 Serotonin Transporter Activity
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4790).
Reference 2 The Synergistic Combination of Everolimus and Paroxetine Exerts Post-ischemic Neuroprotection In Vitro. Cell Mol Neurobiol. 2018 Oct;38(7):1383-1397.
Reference 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China